-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GH-002 in Treatment Resistant Depression
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GH-002 in Treatment Resistant Depression Drug Details:GH-002 is under development for the treatment of treatment resistant...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Sirolimus in Lymphoproliferative Disorders
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Sirolimus in Lymphoproliferative Disorders Drug Details: Sirolimus (Rapatane) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rodatristat Ethyl in Idiopathic Pulmonary Fibrosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Rodatristat Ethyl in Idiopathic Pulmonary Fibrosis Drug Details:Rodatristat ethyl (RVT-1201, KAR-5585) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AZD-5305 in Gastric Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AZD-5305 in Gastric Cancer Drug Details: AZD-5305 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CUE-102 in Metastatic Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CUE-102 in Metastatic Ovarian Cancer Drug Details:CUE-102 is under development for the prevention of wilms’ tumor...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TAK-500 in Esophageal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TAK-500 in Esophageal Cancer Drug Details: TAK-500 is under development for the treatment of metastatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ICT-01 in Diffuse Large B-Cell Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ICT-01 in Diffuse Large B-Cell Lymphoma Drug Details:ICT-01 is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ICT-01 in Follicular Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ICT-01 in Follicular Lymphoma Drug Details:ICT-01 is under development for the treatment of relapsed and refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ETH-155008 in Refractory Chronic Lymphocytic Leukemia (CLL)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ETH-155008 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:ETH-155008 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ICT-01 in Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ICT-01 in Colorectal CancerDrug Details:ICT-01 is under development for the treatment of relapsed and refractory solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ICT-01 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ICT-01 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)Drug Details:ICT-01 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ICT-01 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ICT-01 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Drug Details:ICT-01 is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ICT-01 in Refractory Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ICT-01 in Refractory Acute Myeloid LeukemiaDrug Details:ICT-01 is under development for the treatment of relapsed and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ICT-01 in Relapsed Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ICT-01 in Relapsed Acute Myeloid LeukemiaDrug Details:ICT-01 is under development for the treatment of relapsed and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ICT-01 in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ICT-01 in Pancreatic CancerDrug Details:ICT-01 is under development for the treatment of relapsed and refractory solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ICT-01 in Metastatic Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ICT-01 in Metastatic MelanomaDrug Details:ICT-01 is under development for the treatment of relapsed and refractory solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AFM-24I in Adenocarcinoma Of The Gastroesophageal Junction
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AFM-24I in Adenocarcinoma Of The Gastroesophageal Junction Drug Details: AFM-24I is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RP-3 in Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RP-3 in Melanoma Drug Details: RP-3 is under development for the treatment of advanced solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Copanlisib hydrochloride in Mantle Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Copanlisib hydrochloride in Mantle Cell Lymphoma Drug Details: Copanlisib dihydrochloride (Aliqopa, BAY80-6946) is quinazolinamines derivative...
-
Product Insights
Colon Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colon Cancer Pipeline Drugs Market Overview Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools, and weight loss with...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.